Estimating the magnitude of clinical benefit of systemic therapy in patients with DCIS or pre-invasive disease of the breast-Reference-Cited by-同舟云学术

Estimating the magnitude of clinical benefit of systemic therapy in patients with DCIS or pre-invasive disease of the breast

Published:2019-11 Issue: Volume:48 Page:S39-S43
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Lazzeroni Matteo,Puntoni Matteo,Provinciali Nicoletta,Webber Tania Buttiron,Briata Irene Maria,D’Amico Mauro,Giuliano Silvia,Siri Giacomo,Cagnacci Sara,DeCensi Andrea

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference31 articles.

1. Breast cancer mortality after a diagnosis of ductal carcinoma in situ;Narod;JAMA Oncol,2015

2. Institutional variation in the surgical treatment of breast cancer: A study of the NCCN;Greenberg;Ann Surg,2011

3. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ;Tuttle;J Clin Oncol,2009

4. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: Long-term results from the UK/ANZ DCIS trial;Cuzick;Lancet Oncol,2011

5. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS;Wapnir;J Natl Cancer Inst,2011

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Biology and Management of Ductal Carcinoma in Situ of the Breast;Current Problems in Surgery;2023-08

2. Screen-detected ductal carcinoma in situ, 2008–2020: An observational study;Journal of Medical Screening;2022-03-28

3. Mammaerkrankungen;Facharztwissen Gynäkologie;2021

4. Tamoxifen and Endometrial Cancer: A Janus-Headed Drug;Cancers;2020-09-07